Tracking and Treating Uveitic Macular Edema: A Difficult Dilemma

Uveitic macular edema (UME) has a wide variety of causes. If not appropriately treated, it eventually causes damage to the photoreceptors in the macula, resulting in vision-threatening complications like macular ischemia or macular hole formation. Corticosteroids are the first-line treatment for uveitic inflammation and UME. However, they are not generally considered to be appropriate for long-term treatment due to adverse effects, including increased intraocular pressure and cataract in local therapy, as well as osteonecrosis and adrenal insufficiency with systemic treatment. Although, the development of sustained-release delivery systems may reduce the risk of adverse events. In this educational activity, expert clinicians will assess recent evidence regarding the use of multimodal imaging and biomarkers that aid in the detection and monitoring of UME and evaluate recent clinical data about the use of emerging and approved novel corticosteroid delivery systems in the treatment of UME.